bupivacaine has been researched along with Epicondylitis, Lateral Humeral in 4 studies
Bupivacaine: A widely used local anesthetic agent.
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.
bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.
Excerpt | Relevance | Reference |
---|---|---|
"In a prospective, randomized, double-blind study of radial epicondylalgia (tennis elbow), 109 patients with an average symptom duration of 8 months were considered for treatment with a single 1-mL injection of the steroid triamcinolone combined with either lidocaine or bupivacaine." | 5.08 | Cortisone injection with anesthetic additives for radial epicondylalgia (tennis elbow). ( Adalberth, G; Buch, F; Mallmin, H; Sölveborn, SA, 1995) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Behera, P | 1 |
Dhillon, M | 1 |
Aggarwal, S | 1 |
Marwaha, N | 1 |
Prakash, M | 1 |
Sölveborn, SA | 1 |
Buch, F | 1 |
Mallmin, H | 1 |
Adalberth, G | 1 |
Madan, S | 1 |
Jowett, RL | 1 |
Newcomer, KL | 1 |
Laskowski, ER | 1 |
Idank, DM | 1 |
McLean, TJ | 1 |
Egan, KS | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Tennis Elbow, Randomized Study: Needling With and Without Platelet-rich Plasma After Failure of Up-to-date Rehabilitation[NCT03987256] | 58 participants (Anticipated) | Interventional | 2020-01-01 | Recruiting | |||
Safety and Effects of PDRN(Polydeoxyribonucleotide) Injection in Patient With Elbow Epicondylitis in Randomized Double-blind Active-control Comparative Study[NCT02492945] | Phase 4 | 40 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells: Phase II Double-Blind Placebo-Controlled Randomized Clinical Trials.[NCT02298023] | Phase 2 | 24 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells(ALLO-ASC):A Pilot Study[NCT01856140] | Early Phase 1 | 12 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
Treatment of Epicondylitis by Ultrasound-guided Local Injections of Autologous Conditioned Plasma (ACP®): a Double-blind Placebo-controlled Randomized Clinical Trial With One-year Follow-up[NCT02378285] | 50 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Pain during activity will be evaluated by visual analog scale (active pain VAS). The active pain visual analog scale change from baseline to 3 months after intervention is the primary outcome. Visual analog scale is scored 0 to 10, higher scored meaning worse outcome. Negative values in change of pain during activity indicate improvement in pain. (NCT02298023)
Timeframe: Baseline and 3 months after intervention
Intervention | units on a scale (Mean) |
---|---|
Mesenchymal Stem Cell Group | -1.4 |
Active Control (Fibrin Glue) Group | -1.5 |
Control (Normal Saline )Group | -3.0 |
Functional score of the shoulder was assessed by American Shoulder and Elbow Surgeons shoulder score which is a questionnaire dedicated to the functional evaluation of the shoulder. It is scored from 0 to 100, higher scores meaning better outcome. (NCT02298023)
Timeframe: Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention
Intervention | score on a scale (Mean) | |||||
---|---|---|---|---|---|---|
baseline | week 6 | month 3 | month 6 | month 12 | year 2 | |
Active Control (Fibrin Glue) Group | 64.7 | 70.6 | 73.7 | 76.7 | 76.0 | 80.0 |
Control (Normal Saline )Group | 54.7 | 65.9 | 63.6 | 63.9 | 74.4 | 89.3 |
Mesenchymal Stem Cell Group | 58.9 | 52.4 | 67.9 | 63.4 | 70.6 | 71.6 |
Shoulder function is assessed by DASH score which is questionnaire dedicated to evaluate the function of the upper extremity. It is scored from 0 (no disability) to 100 (most severe disability). (NCT02298023)
Timeframe: Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention
Intervention | score on a scale (Mean) | |||||
---|---|---|---|---|---|---|
baseline | week 6 | month 3 | month 6 | month 12 | year 2 | |
Active Control (Fibrin Glue) Group | 35.2 | 25.8 | 19.2 | 19.8 | 20.5 | 22.8 |
Control (Normal Saline )Group | 37.6 | 28.1 | 28.3 | 27.1 | 20.3 | 20.1 |
Mesenchymal Stem Cell Group | 32.3 | 36.7 | 24.0 | 25.0 | 31.1 | 20.3 |
Pain during activity assessed by visual analog scale (VAS), scored 0 to 10, higher scores meaning worse outcome (NCT02298023)
Timeframe: Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
baseline | week 6 | month 3 | month 6 | month 12 | year 2 | |
Active Control (Fibrin Glue) Group | 4.7 | 3.2 | 3.2 | 2.8 | 3.2 | 3.2 |
Control (Normal Saline )Group | 6.6 | 4.6 | 3.6 | 4.3 | 3.1 | 1.1 |
Mesenchymal Stem Cell Group | 5.7 | 6.0 | 4.4 | 4.3 | 3.7 | 4.4 |
Pain during rest assessed by visual analog scale (VAS), scored 0 to 10, higher scores meaning worse outcome. (NCT02298023)
Timeframe: Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
baseline | week 6 | month 3 | month 6 | month 12 | year 2 | |
Active Control (Fibrin Glue) Group | 2.4 | 2.2 | 1.9 | 1.4 | 1.8 | 0.8 |
Control (Normal Saline )Group | 3.6 | 3.0 | 2.7 | 2.4 | 1.3 | 0.5 |
Mesenchymal Stem Cell Group | 3.9 | 4.0 | 2.8 | 2.9 | 2.9 | 2.0 |
Shoulder function is assessed by UCLA shoulder score which is a composite of range of motion examination and questionnaire dedicated to evaluate the function of the shoulder. It is scored from 0 to 35, higher scores meaning better shoulder function. (NCT02298023)
Timeframe: Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention
Intervention | score on a scale (Mean) | |||||
---|---|---|---|---|---|---|
baseline | week 6 | month 3 | month 6 | month 12 | year 2 | |
Active Control (Fibrin Glue) Group | 19.0 | 22.3 | 23.6 | 23.6 | 24.5 | 24.6 |
Control (Normal Saline )Group | 17.5 | 22.9 | 21.4 | 22.8 | 28.0 | 31.3 |
Mesenchymal Stem Cell Group | 20.3 | 20.0 | 26.4 | 22.7 | 23.6 | 24.4 |
Self reported pain intensity during activity will be evaluated by visual analogue scale (0 = no pain, 10 = pain as bad as can be), higher scores meaning worse outcome. (NCT01856140)
Timeframe: Baseline, 6 weeks, 12 weeks after intervention
Intervention | score on a scale (Mean) | ||
---|---|---|---|
Baseline | Post-injection 6 weeks | Post-injection 12 weeks | |
1 Million Cells/ml of ALLO-ASC | 3.57 | 2.93 | 1.68 |
10 Million Cells/ml of ALLO-ASC | 3.02 | 1.60 | 0.87 |
"Defect areas were measured as the largest defect of the common extensor tendon. Higher value means larger defect area.~With the patient supine position with the elbow in 30' flexion and full pronation, the cephalic end of the ultrasound transducer was placed on the lateral epicondyle and the long axis of the transducer was aligned with the long axis of radius. The alignment of the transducer and radius was achieved by visualizing contours of the bony structures. Multiple cross-sectional images were saved by shifting the transducer medio-laterally by 2mm at a time. Acquiring images were repeated three times.~Among the saved images, one image showing the largest defect were selected for every patients at every time points. Manual measurements of the defect area were conducted by tracking the perimeter using ImageJ 1.48 software (National Institutes of Health, http://imagej.nih.gov/ij/) and were repeated three times by two examiners in random orders and then, averaged." (NCT01856140)
Timeframe: Baseline, 6 weeks, and 12 weeks after the intervention
Intervention | mm^2 (Mean) | ||
---|---|---|---|
Baseline | Post-injection 6weeks | Post-injection 12 weeks | |
1 Million Cells/ml of ALLO-ASC | 4197 | 4163 | 2381 |
10 Million Cells/ml of ALLO-ASC | 5246 | 4383 | 2516 |
"Defect areas were measured as the largest defect of the common extensor tendon. Higher value means larger defect area.~With the patient supine position with the elbow in 30' flexion and full pronation, the transducer was placed on the proximal forearm just distal to the radial head, aligning the long axis of the transducer perpendicular to the long axis of the forearm. Viewing the round radius at the horizontal center, the transducer was shifted proximally by 2mm and multiple images were saved after the transducer passed the radial head until it slid over the prominence. Acquiring images were repeated three times.~Among the saved images, one image showing the largest defect were selected for every patients at every time points. Manual measurements of the defect area were conducted by tracking the perimeter using ImageJ 1.48 software (National Institutes of Health, http://imagej.nih.gov/ij/) and were repeated three times by two examiners in random orders and then, averaged." (NCT01856140)
Timeframe: Baseline, 6 weeks, and 12 weeks after the intervention
Intervention | mm^2 (Mean) | ||
---|---|---|---|
Baseline | Post-injection 6 weeks | Post-injection 12 weeks | |
1 Million Cells/ml of ALLO-ASC | 3726 | 3797 | 2703 |
10 Million Cells/ml of ALLO-ASC | 5018 | 2849 | 2223 |
The Modified Mayo clinic performance index for the elbow measures pain, motion, stability, and daily functions. (0 to 100) Higher score means better function. (NCT01856140)
Timeframe: Baseline, 6 weeks, 12 weeks after the intervention
Intervention | score on a scale (Median) | ||
---|---|---|---|
Baseline | Post-injection 6 weeks | Post-injection 12 weeks | |
1 Million Cells/ml of ALLO-ASC | 57.92 | 83.75 | 87.92 |
10 Million Cells/ml of ALLO-ASC | 70.00 | 90.41 | 91.67 |
3 trials available for bupivacaine and Epicondylitis, Lateral Humeral
Article | Year |
---|---|
Leukocyte-poor platelet-rich plasma versus bupivacaine for recalcitrant lateral epicondylar tendinopathy.
Topics: Adult; Anesthetics, Local; Bupivacaine; Female; Glucocorticoids; Humans; Injections; Male; Middle Ag | 2015 |
Cortisone injection with anesthetic additives for radial epicondylalgia (tennis elbow).
Topics: Adolescent; Adult; Aged; Bupivacaine; Double-Blind Method; Drug Combinations; Female; Humans; Lidoca | 1995 |
Cortisone injection with anesthetic additives for radial epicondylalgia (tennis elbow).
Topics: Adolescent; Adult; Aged; Bupivacaine; Double-Blind Method; Drug Combinations; Female; Humans; Lidoca | 1995 |
Cortisone injection with anesthetic additives for radial epicondylalgia (tennis elbow).
Topics: Adolescent; Adult; Aged; Bupivacaine; Double-Blind Method; Drug Combinations; Female; Humans; Lidoca | 1995 |
Cortisone injection with anesthetic additives for radial epicondylalgia (tennis elbow).
Topics: Adolescent; Adult; Aged; Bupivacaine; Double-Blind Method; Drug Combinations; Female; Humans; Lidoca | 1995 |
Cortisone injection with anesthetic additives for radial epicondylalgia (tennis elbow).
Topics: Adolescent; Adult; Aged; Bupivacaine; Double-Blind Method; Drug Combinations; Female; Humans; Lidoca | 1995 |
Cortisone injection with anesthetic additives for radial epicondylalgia (tennis elbow).
Topics: Adolescent; Adult; Aged; Bupivacaine; Double-Blind Method; Drug Combinations; Female; Humans; Lidoca | 1995 |
Cortisone injection with anesthetic additives for radial epicondylalgia (tennis elbow).
Topics: Adolescent; Adult; Aged; Bupivacaine; Double-Blind Method; Drug Combinations; Female; Humans; Lidoca | 1995 |
Cortisone injection with anesthetic additives for radial epicondylalgia (tennis elbow).
Topics: Adolescent; Adult; Aged; Bupivacaine; Double-Blind Method; Drug Combinations; Female; Humans; Lidoca | 1995 |
Cortisone injection with anesthetic additives for radial epicondylalgia (tennis elbow).
Topics: Adolescent; Adult; Aged; Bupivacaine; Double-Blind Method; Drug Combinations; Female; Humans; Lidoca | 1995 |
Corticosteroid injection in early treatment of lateral epicondylitis.
Topics: Adolescent; Adult; Aged; Anesthetics, Local; Anti-Inflammatory Agents; Athletic Injuries; Betamethas | 2001 |
1 other study available for bupivacaine and Epicondylitis, Lateral Humeral
Article | Year |
---|---|
Lateral epicondylalgia: treatment by manipulation under anaesthetic and steroid injection and operative release.
Topics: Adult; Anesthetics, Local; Anti-Inflammatory Agents; Bupivacaine; Combined Modality Therapy; Female; | 2000 |